Akebia Therapeutics Inc (AKBA) concluded trading on Thursday at a closing price of $2.62, with 10.58 million shares of worth about $27.73 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 41.62% during that period and on May 08, 2025 the price saw a gain of about 6.50%. Currently the company’s common shares owned by public are about 261.79M shares, out of which, 251.04M shares are available for trading.
Stock saw a price change of 9.62% in past 5 days and over the past one month there was a price change of 55.95%. Year-to-date (YTD), AKBA shares are showing a performance of 37.89% which increased to 75.84% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.80 but also hit the highest price of $2.89 during that period. The average intraday trading volume for Akebia Therapeutics Inc shares is 4.14 million. The stock is currently trading 19.74% above its 20-day simple moving average (SMA20), while that difference is up 27.61% for SMA50 and it goes to 46.43% higher than SMA200.
Akebia Therapeutics Inc (NASDAQ: AKBA) currently have 261.79M outstanding shares and institutions hold larger chunk of about 25.94% of that.
The stock has a current market capitalization of $685.88M and its 3Y-monthly beta is at 0.77. It has posted earnings per share of -$0.33 in the same period. It has Quick Ratio of 1.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AKBA, volatility over the week remained 6.75% while standing at 7.21% over the month.
Stock’s fiscal year EPS is expected to rise by 67.88% while it is estimated to increase by 118.87% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on April 28, 2025 offering an Outperform rating for the stock and assigned a target price of $7 to it. Coverage by Jefferies stated Akebia Therapeutics Inc (AKBA) stock as a Buy in their note to investors on April 01, 2025, suggesting a price target of $6 for the stock. On November 29, 2023, BTIG Research Resumed their recommendations, while on August 28, 2023, H.C. Wainwright Upgrade their ratings for the stock with a price target of $3.75. Stock get an Overweight rating from Piper Sandler on May 31, 2023.
